Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CODX

CODX - Co-Diagnostics Inc Stock Price, Fair Value and News

$2.820.00 (0.00%)
Market Closed

81/100

CODX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

81/100

CODX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$4.24

Target 3M

$3.46

Target 6M

$3.82

CODX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CODX Price Action

Last 7 days

-4.1%

Last 30 days

-58.9%

Last 90 days

-79.9%

Trailing 12 Months

-88.0%

CODX RSI Chart

CODX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CODX Valuation

Market Cap

5.7M

Price/Earnings (Trailing)

-0.18

Price/Sales (Trailing)

1.55

EV/EBITDA

0.18

Price/Free Cashflow

-0.18

CODX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$4.24

Target 3M

$3.46

Target 6M

$3.82

CODX Fundamentals

CODX Revenue

Revenue (TTM)

3.9M

Rev. Growth (Yr)

-77.32%

Rev. Growth (Qtr)

-10.76%

CODX Earnings

Earnings (TTM)

-32.2M

Earnings Growth (Yr)

39.29%

Earnings Growth (Qtr)

23.85%

CODX Profitability

Operating Margin

91.44%

EBT Margin

-851.35%

Return on Equity

-80.8%

Return on Assets

-71.93%

Free Cashflow Yield

-555.73%

CODX Investor Care

Shares Dilution (1Y)

90.71%

Diluted EPS (TTM)

-29.7

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20246.7M9.1M7.3M3.9M
202327.4M20.5M13.7M6.8M
2022100.6M78.2M53.2M34.2M
202193.0M96.3M104.6M97.9M
202000074.6M
20190000
201815.7K23.8K31.8K39.9K
20170007.7K
Get all data in R, Python etc through our Historical Stock Data APIs

About Co-Diagnostics Inc

CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
 CEO
 WEBSITEcodiagnostics.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES145

Co-Diagnostics Inc Frequently Asked Questions

CODX is the stock ticker symbol of Co-Diagnostics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Co-Diagnostics Inc is 5.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CODX's fair value in chart for subscribers.

The fair value guage provides a quick view whether CODX is over valued or under valued. Whether Co-Diagnostics Inc is cheap or expensive depends on the assumptions which impact Co-Diagnostics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CODX.

As of Wed Jan 28 2026, CODX's PE ratio (Price to Earnings) is -0.18 and Price to Sales (PS) ratio is 1.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CODX PE ratio will change depending on the future growth rate expectations of investors.